Entity
  • Amber Therapeutics

    Created in 2021
  • BETA

    Trend leader (A+)
    Existing signals make this entity one of the most dynamic startups
  • Social networks

    3,226
  • Activities

  • Technologies

  • Entity types

  • Location

    242 Acklam Rd, London W10 5JJ, UK

    London

    United Kingdom

  • Employees

    Scale: 11-50

    Estimated: 33

  • Engaged corporates

    2
    2 0
  • Added in Motherbase

    1 year, 8 months ago
Description
  • Value proposition

    Doing the extraordinary to restore the ordinary

    Amber Therapeutics was founded in 2021 with a mission to develop and deliver breakthrough neuromodulation therapies that can fundamentally transform outcomes in areas of unmet clinical need. With the acquisition of Finetech Medical Limited and Bioinduction Ltd in 2023, we are continuing to be the only UK based company in the field of designing and manufacturing long-term implantables.

    We have since grown into a multidisciplinary team, combining deep medical device experience with a culture and mindset focused on transformational innovation.

    Amber UI is the company’s first therapy, aiming to restore normal physiological function in women suffering with mixed urinary incontinence.

  • Amber Therapeutics - Home

    Doing the extraordinary‍ to restore the ordinary. We’re developing the first adaptive neuromodulation therapy that is able to treat women suffering with mixed incontinence.

  • https://www.amber-tx.com/
Corporate interactions BETA
Corporate TypeTweets Articles
Oxford Science Enterprises
Oxford Science Enterprises
Startup accelerator & VC, Venture Capital and Private Equity Principals
Oxford Science Enterprises
Startup accelerator & VC, Venture Capital and Private Equity Principals
Other

31 Jul 2024


Oxford University Innovation
Oxford University Innovation
Research, Financial Services
Oxford University Innovation
Research, Financial Services
Other

24 Jul 2024


Similar entities
Loading...
Loading...
Social network dynamics